Sentences with phrase «in mouse models of breast cancer»

Future studies will test and compare the efficacy of imatinib and allosteric compounds in mouse models of breast cancer.

Working in mouse models of breast cancer and breast tumor samples from patients, Longmore and his colleagues showed that a protein that sits on the surface of tumor cells, called DDR2, binds to collagen and activates a multistep pathway that encourages tumor cells to spread.

When the team used the retinoid fenretinide along with anti-estrogen therapy in mouse models of breast cancer, they did not see the expansion of CK5 + cells previously seen with anti-estrogen therapy alone.

Then they removed the protein in a mouse model of breast cancer and discovered the cancer's ability to spread was significantly reduced.

Similar results were observed in a mouse model of breast cancer.

T - cells (red, yellow, and blue) attack a tumour in a mouse model of breast cancer following treatment with radiation and a PD - L1 immune checkpoint inhibitor, as seen by transparent tumour tomography.

Moreover, ablation of a STAT5A allele reduces tumor incidence in a mouse model of breast cancer in which mammary epithelial cells express T antigen (48).

Not exact matches

The researchers tested their drug compound, Targapremir - 210, in mouse models of triple negative breast cancer.

«Indeed, in a second tumor model of metastatic breast cancer, we demonstrated that mice treated with the EphA2 - targeting paclitaxel conjugate presented nearly no lung metastases, while a large numbers of lesions were observed in both untreated mice and in mice treated with just paclitaxel.»

Recent collaborative work between UCR and Cedars - Sinai Medical Center in Los Angeles demonstrated that in animal models of human breast cancer, mice treated with 123B9 that was conjugated with paclitaxel had significantly fewer circulating cancer cells in the blood compared to mice that were not treated or even treated with paclitaxel alone.

In the Cell study, Dr. Massagué, with Fellow Manuel Valiente, PhD, and other team members, found that in mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocyteIn the Cell study, Dr. Massagué, with Fellow Manuel Valiente, PhD, and other team members, found that in mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocytein mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocytes.

The research, conducted in cell lines and mouse models, explored enhancing the cancer - killing effects of PARP inhibitors not only in regard to AML but also triple - negative breast cancer.

In a mouse model of triple - negative breast cancer, mice injected with cancer cells that over-express ZMYND11 had tumor volumes of less than 50 cubic millimeters while control mice and those injected with cells expressing ZMYND11 deficient for binding to the methyl group had tumor volumes ranging from 150 to 400 cubic millimeters at eight weeks.

Treatment in a mouse model of metastatic breast cancer with two of the down - regulated miRNAs (miR - 141 and miR - 219) suppressed bone metastases, suggesting that these miRNAs may have therapeutic utility.

Working with human breast cancer cells and mouse models of breast cancer, scientists identified a new protein that plays a key role in reprogramming cancer cells to migrate and invade other organs.

Witt - Enderby at Duquesne is using her expertise in molecular pharmacology to study the effects of melatonin on a mouse breast cancer model.

In a four - year study conducted on the mouse model in advanced breast cancer metastasis in the eye's anterior chamber, Petty and colleagues found that the new nanoparticle not only killed tumor cells in the eye, but also extended the survival of experimental mice bearing 4T1 tumors, a cell line that is extremely difficult to kilIn a four - year study conducted on the mouse model in advanced breast cancer metastasis in the eye's anterior chamber, Petty and colleagues found that the new nanoparticle not only killed tumor cells in the eye, but also extended the survival of experimental mice bearing 4T1 tumors, a cell line that is extremely difficult to kilin advanced breast cancer metastasis in the eye's anterior chamber, Petty and colleagues found that the new nanoparticle not only killed tumor cells in the eye, but also extended the survival of experimental mice bearing 4T1 tumors, a cell line that is extremely difficult to kilin the eye's anterior chamber, Petty and colleagues found that the new nanoparticle not only killed tumor cells in the eye, but also extended the survival of experimental mice bearing 4T1 tumors, a cell line that is extremely difficult to kilin the eye, but also extended the survival of experimental mice bearing 4T1 tumors, a cell line that is extremely difficult to kill.

Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research from Washington University School of Medicine in St. Louis.

«Unusual drug generates exciting results in mouse models of metastatic breast cancer.»

The team's next steps are to test coibamide A in a mouse model for triple negative breast cancer and in a mouse model for brain cancer in which the glioblastoma cells are grown in the brain instead of the flank.

A new study shows coibamide A has potent anti-cancer activity in mice and cell cultures that model brain tumors and triple negative breast cancer, two of the most aggressive and difficult - to - treat types of cancer.

After confirming in mouse models that cells from HER2 - positive breast cancers became resistant to anti-HER2 treatment when implanted into the brain but not into other tissues, the investigators found that HER3 is overexpressed in brain metastases of HER2 - positive breast cancers from both mice and human patients.

Additionally, the study showed that genetic knockdown of RASAL2 gene can lead to reduced metastasis in breast cancer mouse model.

2) The two repeated experiments analyze the source of POSTN expression in the lung and whether it affects the number / size of primary and secondary tumor formation in a spontaneous mouse model of breast cancer (MMTV - PyMT).

Tagged therapeutic stem cells (green) are targeting breast cancer metastases (red) in the brain of a mouse model.

We'll test this in other models — with other classes of drug and in mice with a cancer that mimics metastatic breast cancer, for example.»

Therefore, we have explored the role of the alpha2 beta1 integrin in cancer initiation and progression using a clinically - relevant, spontaneous mouse model, the MMTV - Neu model of breast cancer progression and metastasis.

Now, in Stem Cells Translation Medicine, the group of Shu Wang at the National University of Singapore describe the derivation of EPCs from human iPSCs, their therapeutic modification, and their ability to inhibit tumor growth in a mouse breast cancer model [4].

Unlike previous MRI studies of tumors in mice, the researchers were able to detect very small naturally occurring cancers, which were excellent models for human breast cancer; the tumors the mice developed were «realistic models of the most frequently detected human cancers,» the authors wrote.

The authors then tested the tumor targeting capability of iPSC - EPCs labelled with the near - infrared fluorescent dye DiR in two established mouse breast cancer models.

We found that allosteric inhibition of the ABL kinases effectively impaired breast cancer bone metastasis and blocked tumor - induced osteolysis in mouse models.

Together, our findings suggest that ABL kinases activate the TAZ and STAT5 pathways and that coactivation of their downstream targets promote the bone metastasis of breast cancer cells in mouse models.

The King lab is currently testing these novel cancer therapies in mouse models of metastatic breast and prostate cancer through the use of whole body luminescence imaging.

Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer

In the present study, we interrogated the role of this transporter in breast cancer by deleting Slc6a14 in mice and monitoring the consequences of this deletion in models of spontaneous breast cancer (Polyoma middle T oncogene - transgenic mouse and mouse mammary tumour virus promoter - Neu - transgenic mouseIn the present study, we interrogated the role of this transporter in breast cancer by deleting Slc6a14 in mice and monitoring the consequences of this deletion in models of spontaneous breast cancer (Polyoma middle T oncogene - transgenic mouse and mouse mammary tumour virus promoter - Neu - transgenic mousein breast cancer by deleting Slc6a14 in mice and monitoring the consequences of this deletion in models of spontaneous breast cancer (Polyoma middle T oncogene - transgenic mouse and mouse mammary tumour virus promoter - Neu - transgenic mousein mice and monitoring the consequences of this deletion in models of spontaneous breast cancer (Polyoma middle T oncogene - transgenic mouse and mouse mammary tumour virus promoter - Neu - transgenic mousein models of spontaneous breast cancer (Polyoma middle T oncogene - transgenic mouse and mouse mammary tumour virus promoter - Neu - transgenic mouse).

These kind of mice are an extraordinary resource for modeling human disease; for instance, research has found that mice that are genetically mutated to carry the BRCA1 gene (a human breast cancer gene) behave more similarly to human cancer patients than those mice who have had a tumor physically transplanted in.

Last year, Mandriota and collaborators demonstrated that in a cancer mouse model, concentrations of aluminum in the amount of those measured in the human breast are able to transform cultured mammary epithelial cells, allowing them to form tumors and to metastasize.

Our mouse model data are not in conflict with the epidemiological observation that a first pregnancy before age 22 greatly reduces breast cancer risk (MacMahon et al., 1970), because at this young age, the chance of having already accumulated precancerous cells is small.